Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1987 1
1988 1
1989 2
1990 2
1991 1
1992 4
1993 10
1994 1
1995 3
1997 2
1999 2
2000 5
2001 4
2002 4
2003 1
2004 6
2006 7
2007 3
2009 1
2010 3
2011 6
2012 9
2013 5
2014 6
2015 6
2016 3
2017 5
2018 4
2019 5
2020 5
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 12148575

112 results

Results by year

Filters applied: . Clear all
Page 1
Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
García-Del-Muro X, López-Pousa A, Maurel J, Martín J, Martínez-Trufero J, Casado A, Gómez-España A, Fra J, Cruz J, Poveda A, Meana A, Pericay C, Cubedo R, Rubió J, De Juan A, Laínez N, Carrasco JA, de Andrés R, Buesa JM; Spanish Group for Research on Sarcomas. García-Del-Muro X, et al. J Clin Oncol. 2011 Jun 20;29(18):2528-33. doi: 10.1200/JCO.2010.33.6107. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606430 Clinical Trial.
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ, Chugh R, Zhao L, Lucas DR, Biermann JS, Zalupski MM, Feng M, Wong SL, Jacobson J, Zyczynski L, Reinke D, Metko G, Baker LH, Schuetze SM. Davis EJ, et al. Eur J Cancer. 2015 Sep;51(13):1794-802. doi: 10.1016/j.ejca.2015.05.010. Epub 2015 Jun 9. Eur J Cancer. 2015. PMID: 26066736 Clinical Trial.
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Gronchi A, et al. Lancet Oncol. 2017 Jun;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9. Lancet Oncol. 2017. PMID: 28499583 Clinical Trial.
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
Leyvraz S, Herrmann R, Guillou L, Honegger HP, Christinat A, Fey MF, Sessa C, Wernli M, Cerny T, Dietrich D, Pestalozzi B; Swiss Group for Clinical Cancer Research (SAKK). Leyvraz S, et al. Br J Cancer. 2006 Nov 20;95(10):1342-7. doi: 10.1038/sj.bjc.6603420. Epub 2006 Oct 10. Br J Cancer. 2006. PMID: 17031396 Free PMC article. Clinical Trial.
Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Kaya AO, Büyükberber S, Ozkan M, Alkiş N, Sevinc A, Ozdemir NY, Alici S, Esbah O, Berk V, Camci C, Ulas A, Coskun U, Benekli M; Anatolian Society of Medical Oncology (ASMO). Kaya AO, et al. Asian Pac J Cancer Prev. 2012;13(2):463-7. doi: 10.7314/apjcp.2012.13.2.463. Asian Pac J Cancer Prev. 2012. PMID: 22524807 Free article.
112 results